JPWO2020123991A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020123991A5 JPWO2020123991A5 JP2021531115A JP2021531115A JPWO2020123991A5 JP WO2020123991 A5 JPWO2020123991 A5 JP WO2020123991A5 JP 2021531115 A JP2021531115 A JP 2021531115A JP 2021531115 A JP2021531115 A JP 2021531115A JP WO2020123991 A5 JPWO2020123991 A5 JP WO2020123991A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- crenolanib
- pharmaceutical composition
- per day
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950009240 Crenolanib Drugs 0.000 claims 37
- DYNHJHQFHQTFTP-UHFFFAOYSA-N Crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- -1 capcitabine Chemical compound 0.000 claims 17
- 102100013180 KDR Human genes 0.000 claims 15
- 108091007928 VEGF receptors Proteins 0.000 claims 15
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 14
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 14
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 13
- 230000002062 proliferating Effects 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 229960003005 axitinib Drugs 0.000 claims 11
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 11
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 9
- 210000003236 Esophagogastric Junction Anatomy 0.000 claims 6
- 206010017758 Gastric cancer Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 208000000649 Small Cell Carcinoma Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 201000011549 stomach cancer Diseases 0.000 claims 6
- 239000002168 alkylating agent Substances 0.000 claims 5
- 239000002256 antimetabolite Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 229960002949 Fluorouracil Drugs 0.000 claims 4
- 230000000340 anti-metabolite Effects 0.000 claims 4
- 229960001756 oxaliplatin Drugs 0.000 claims 4
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 claims 3
- NOGSKCDVWBOZAQ-UWEASSQTSA-N (3E)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one;(2S)-2-hydroxypropanoic acid;hydrate Chemical compound O.C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 NOGSKCDVWBOZAQ-UWEASSQTSA-N 0.000 claims 3
- CXQHYVUVSFXTMY-UHFFFAOYSA-N 1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims 3
- GNNDEPIMDAZHRQ-UHFFFAOYSA-N 1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1(C(=O)NC=2C(=CC(OC=3C=C(NC(=O)C4CC4)N=CC=3)=C(F)C=2)F)CC1 GNNDEPIMDAZHRQ-UHFFFAOYSA-N 0.000 claims 3
- MCTXSDCWFQAGFS-UEXNTNOUSA-N 2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-5-[(2R)-2-hydroxy-3-morpholin-4-ylpropyl]-3-methyl-1,6,7,8-tetrahydropyrrolo[3,2-c]azepin-4-one Chemical compound C([C@@H](O)CN1CCCC=2NC(\C=C/3C4=CC(F)=CC=C4NC\3=O)=C(C=2C1=O)C)N1CCOCC1 MCTXSDCWFQAGFS-UEXNTNOUSA-N 0.000 claims 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- GKEYKDOLBLYGRB-LGMDPLHJSA-N 5-[2-(diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one Chemical compound O=C\1NC2=CC=C(F)C=C2C/1=C/C(N1)=C(C)C2=C1CCN(CCN(CC)CC)C2=O GKEYKDOLBLYGRB-LGMDPLHJSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 3
- 208000009956 Adenocarcinoma Diseases 0.000 claims 3
- 229950005952 Altiratinib Drugs 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 3
- 108091021654 BEVZ92 Proteins 0.000 claims 3
- 108010005144 Bevacizumab Proteins 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 229950000025 Brolucizumab Drugs 0.000 claims 3
- 229960004562 Carboplatin Drugs 0.000 claims 3
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 229950005748 Conbercept Drugs 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229960004679 Doxorubicin Drugs 0.000 claims 3
- 229950008692 Foretinib Drugs 0.000 claims 3
- 208000005017 Glioblastoma Diseases 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 3
- 108010063936 IBI302 Proteins 0.000 claims 3
- 108010026702 IMC1C11 Proteins 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 108010047080 KH902 fusion protein Proteins 0.000 claims 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 3
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 3
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 3
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 3
- WOSKHXYHFSIKNG-UHFFFAOYSA-N Lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 3
- 229950002216 Linifanib Drugs 0.000 claims 3
- MPVGZUGXCQEXTM-UHFFFAOYSA-N Linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 3
- 229950010895 Midostaurin Drugs 0.000 claims 3
- 229950003968 Motesanib Drugs 0.000 claims 3
- RAHBGWKEPAQNFF-UHFFFAOYSA-N Motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims 3
- WPEWQEMJFLWMLV-UHFFFAOYSA-N N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- XZXHXSATPCNXJR-ZIADKAODSA-N Nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 3
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 229960001592 Paclitaxel Drugs 0.000 claims 3
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 108010062724 Ranibizumab Proteins 0.000 claims 3
- 229960003876 Ranibizumab Drugs 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 3
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 3
- 101700058028 TX16 Proteins 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000008732 Thymoma Diseases 0.000 claims 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 3
- 206010046766 Uterine cancer Diseases 0.000 claims 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 3
- 229950000449 Vanucizumab Drugs 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 229960002833 aflibercept Drugs 0.000 claims 3
- 108010081667 aflibercept Proteins 0.000 claims 3
- 108010089411 angiocal protein Proteins 0.000 claims 3
- 230000001028 anti-proliferant Effects 0.000 claims 3
- 229960003982 apatinib Drugs 0.000 claims 3
- ARQUTWAXTHJROR-UHFFFAOYSA-N benzenesulfonic acid;1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine Chemical group OS(=O)(=O)C1=CC=CC=C1.C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 ARQUTWAXTHJROR-UHFFFAOYSA-N 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 108010064095 brolucizumab Proteins 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 201000011231 colorectal cancer Diseases 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 3
- 229960003784 lenvatinib Drugs 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000001394 metastastic Effects 0.000 claims 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 3
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 3
- 229960004378 nintedanib Drugs 0.000 claims 3
- 229960000639 pazopanib Drugs 0.000 claims 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 3
- 229960005079 pemetrexed Drugs 0.000 claims 3
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 229960001131 ponatinib Drugs 0.000 claims 3
- 229960002633 ramucirumab Drugs 0.000 claims 3
- 108010026911 ramucirumab Proteins 0.000 claims 3
- 229960004836 regorafenib Drugs 0.000 claims 3
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 229960003787 sorafenib Drugs 0.000 claims 3
- 229940086735 succinate Drugs 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 3
- 229960001796 sunitinib Drugs 0.000 claims 3
- 229930003347 taxol Natural products 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 229960000303 topotecan Drugs 0.000 claims 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 229960000241 vandetanib Drugs 0.000 claims 3
- 108010022795 vanucizumab Proteins 0.000 claims 3
- 229960002760 ziv-aflibercept Drugs 0.000 claims 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 2
- 229960001561 Bleomycin Drugs 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004630 Chlorambucil Drugs 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 229960004397 Cyclophosphamide Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- 229960001904 EPIRUBICIN Drugs 0.000 claims 2
- 229960001842 Estramustine Drugs 0.000 claims 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 2
- 229960005420 Etoposide Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 2
- 229960000961 Floxuridine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- 229960001101 Ifosfamide Drugs 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 229960004857 Mitomycin Drugs 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 229960001156 Mitoxantrone Drugs 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 229950007221 Nedaplatin Drugs 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 229960001052 Streptozocin Drugs 0.000 claims 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 2
- 229960001278 Teniposide Drugs 0.000 claims 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 2
- 229960003048 Vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 Vincristine Drugs 0.000 claims 2
- 229960004355 Vindesine Drugs 0.000 claims 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 2
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 229960001573 cabazitaxel Drugs 0.000 claims 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 229960002412 cediranib Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000003511 endothelial Effects 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229960002247 lomustine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 229960004432 raltitrexed Drugs 0.000 claims 2
- 229960000653 valrubicin Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960000922 vinflunine Drugs 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 2
- 230000003442 weekly Effects 0.000 claims 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- 229960004117 Capecitabine Drugs 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 229960002293 Leucovorin Calcium Drugs 0.000 claims 1
- 102100004939 PDGFRB Human genes 0.000 claims 1
- 101710018346 PDGFRB Proteins 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims 1
- 235000008207 calcium folinate Nutrition 0.000 claims 1
- 239000011687 calcium folinate Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 239000005445 natural product Substances 0.000 claims 1
- 229930014626 natural products Natural products 0.000 claims 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 230000002250 progressing Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000007196 sexual disease Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779128P | 2018-12-13 | 2018-12-13 | |
| US62/779,128 | 2018-12-13 | ||
| US201962861424P | 2019-06-14 | 2019-06-14 | |
| US62/861,424 | 2019-06-14 | ||
| PCT/US2019/066308 WO2020123991A1 (en) | 2018-12-13 | 2019-12-13 | Crenolanib combination therapy |
| US16/713,935 | 2019-12-13 | ||
| US16/713,935 US11602533B2 (en) | 2018-12-13 | 2019-12-13 | Crenolanib combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510962A JP2022510962A (ja) | 2022-01-28 |
| JPWO2020123991A5 true JPWO2020123991A5 (zh) | 2022-12-20 |
Family
ID=69596002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531115A Pending JP2022510962A (ja) | 2018-12-13 | 2019-12-13 | クレノラニブ併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11602533B2 (zh) |
| EP (1) | EP3893874A4 (zh) |
| JP (1) | JP2022510962A (zh) |
| CN (1) | CN110840893A (zh) |
| WO (1) | WO2020123991A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
| CN113491693B (zh) * | 2020-03-19 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途 |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US20220047574A1 (en) * | 2020-08-15 | 2022-02-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pdgfr alpha mutated proliferative disorders |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| CN118576611A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗尤文氏肉瘤的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| ES2315663T3 (es) | 2003-06-24 | 2009-04-01 | Pfizer Products Incorporated | Procedimiento para la preparacion de derivados de 1-((benzoimidazol-1-il)quinolin-8-il)piperidin-4-ilamina. |
| US20130230511A1 (en) * | 2012-02-03 | 2013-09-05 | Board Of Regents, The University Of Texas System | Biomarkers for response to tyrosine kinase pathway inhibitors in cancer |
| JP6407504B2 (ja) * | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| CN105007939B (zh) * | 2012-10-05 | 2018-10-19 | 卡德门企业有限公司 | 人抗vegfr-2/kdr抗体 |
| MX2015005839A (es) * | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| EP3060654B1 (en) * | 2013-10-21 | 2023-03-15 | Hemoshear, LLC | In vitro model for a tumor microenvironment |
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
-
2019
- 2019-09-26 CN CN201910917756.5A patent/CN110840893A/zh active Pending
- 2019-12-13 EP EP19896570.9A patent/EP3893874A4/en active Pending
- 2019-12-13 WO PCT/US2019/066308 patent/WO2020123991A1/en unknown
- 2019-12-13 US US16/713,935 patent/US11602533B2/en active Active
- 2019-12-13 JP JP2021531115A patent/JP2022510962A/ja active Pending
-
2023
- 2023-02-09 US US18/166,636 patent/US20230181565A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3524268A1 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| CN107864625B (zh) | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 | |
| US11602533B2 (en) | Crenolanib combination therapy | |
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| Bittoni et al. | Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. | |
| Iwase et al. | Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| Schmitt et al. | Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Groupe | |
| JP2003533485A5 (zh) | ||
| JPWO2020123991A5 (zh) | ||
| JP2019536783A5 (zh) | ||
| Segawa et al. | A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503 | |
| CN112236147A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 | |
| JPWO2016024595A1 (ja) | エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物 | |
| Kamura et al. | Chemotherapy for advanced or recurrent cervical cancer | |
| CN112218639A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合组合物和其使用方法 | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| WO2021018310A1 (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| CN106255500A (zh) | 用于治疗癌症的新的头孢菌素衍生物 | |
| Mizushima et al. | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer | |
| KR20160038895A (ko) | 암 화학 요법시의 부작용 경감제 | |
| Geoffroy et al. | Chemotherapy of advanced gastrointestinal cancer | |
| CN106176757B (zh) | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 | |
| US20150374702A1 (en) | Anticancer adjuvant containing pentoxifylline |